Dr Cécile Le Péchoux talked to ecancer online about the LungART trial presented at the ESMO 2020 virtual meeting this year. She initially outlined the reasoning for the LungART phase III clinical trial, and explained the end-points evaluated in this trial.
Dr Le Perchoux then went into some detail regarding the outcomes observed between the PORT arm and the chemotherapy arm. She explained how through this trial PORT has proven to not be essential for fully resected NSCLC patients.
However, it might still be useful for certain patients and that needs to be further looked into.
Dr Le Péchoux wrapped up with her expectations for the future of this work, and the potential implications this trial has on the clinical landscape of non-small cell lung cancer (NSCLC).
See related news here.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.